Pfizer’s clinical research unit in Brussels is a leading research facility that conducts mostly phase 1 clinical trials. Pfizer has two clinical research units: one in New Haven (Connecticut, USA) and the other in Brussels, located on the university campus of Erasmus Hospital. The Brussels PCRU is a modern facility occupying the top two floors of the day hospital of Erasmus Hospital. It has a capacity of 72 beds and includes examination rooms, a laboratory, and a pharmacy.
Since it opened in 1992, the Brussels PCRU has enabled the development of many medicines, running more than 500 phase 1 clinical studies with the help of several thousand participants. The PCRU’s qualified staff of doctors, nurses, pharmacists, laboratory technicians, and administrative employees work together to run these clinical studies and, in so doing, ultimately help patients around the world.
The Brussels PCRU has also extended its activities to the nearby Centre Administratif Hospitalier (CAH) building, where the PCRU conducts clinical research screening and other outpatient study activities. Pfizer also operates a satellite site in Hasselt, on the Salvator campus of Jessa Hospital. This site provides participants with the option to attend outpatient visits in Hasselt rather than in Brussels.
The majority of clinical studies at the Brussels PCRU are conducted on behalf of study teams located in the United States: Groton (Connecticut), New York (New York), La Jolla (California), Cambridge (Massachusetts), Collegeville (Pennsylvania) and Boulder (Colorado), as well as in China and Japan.